Advertisement

SABCS 2015: No Significant Difference in Recurrence Rates Among Women With Ductal Carcinoma in Situ Taking Anastrozole or Tamoxifen

Advertisement

Key Points

  • Women in both the anastrozole and tamoxifen groups had similar overall efficacy, with slightly better outcomes for those who took anastrozole.
  • There were no significant differences across subgroups except for invasive cancer recurrences: Women taking anastrozole were less likely to have HER2-negative invasive cancer recurrences, whereas women taking tamoxifen were less likely to have HER2-positive invasive cancer recurrences.
  • Women who took anastrozole experienced fewer endometrial and ovarian cancers and skin cancers compared with those who took tamoxifen. However, more strokes were seen among those receiving anastrozole. Data were not sufficiently mature to assess differences in death rates. 

Postmenopausal women with ductal carcinoma in situ (DCIS) had similar outcomes with disease recurrence whether they took tamoxifen or the aromatase inhibitor anastrozole for 5 years after surgery, but women in the two groups had different side effects, according to results from the phase III IBIS-II DCIS clinical trial presented by Cuzick et al at the 2015 San Antonio Breast Cancer Symposium, held December 8–12 in San Antonip, Texas (Abstract S6-03). This study was published simultaneously by Forbest et al in The Lancet.

Study Details

“The IBIS-II DCIS study followed on from the ATAC and other aromatase inhibitor trials that showed aromatase inhibitors were more effective than tamoxifen in preventing recurrence of hormone receptor–positive invasive breast cancer in postmenopausal women,” said Jack Cuzick, PhD, Professor and Director of the Wolfson Institute of Preventive Medicine at Queen Mary University of London. “Given the paucity of data on the effect of aromatase inhibitors on DCIS, it was a natural step to explore them for women with DCIS.

“In this trial, we found that the anastrozole and tamoxifen groups showed similar overall efficacy, with slightly better outcomes for those who took anastrozole. The side-effect profiles were very different for the two drugs; however, the patients had identical compliance and balancing side effects,” Dr. Cuzick added. “Anastrozole offers another choice for treating patients with estrogen receptor–positive DCIS. Choice may depend more on tolerability and existing conditions related to side effects than efficacy,” he said.

In this multicenter, randomized, placebo-controlled trial, 2,980 postmenopausal women with locally excised hormone receptor–positive DCIS were enrolled; 1,471 were randomly assigned anastrozole at 1 mg/d and 1,509 were randomly assigned to tamoxifen at 20 mg/d. All women also received a placebo that looked like the test drug they did not receive in order to ensure that the side-effect profile assessments were reliable, Dr. Cuzick explained. The primary endpoint of the study was breast cancer recurrence.

Key Findings

After a median follow-up of 7.2 years, 144 participants developed breast cancer, and 69 died; 4 deaths were due to breast cancer. Women who took anastrozole had an 11% lower rate of recurrence of DCIS or invasive cancer than those who took tamoxifen, but this difference was not significant.

There were no significant differences across subgroups except for invasive cancer recurrences: Women taking anastrozole were less likely to have HER2-negative invasive cancer recurrences, whereas women taking tamoxifen were less likely to have HER2-positive invasive cancer recurrences.

Women who took anastrozole experienced fewer endometrial, ovarian, and skin cancers compared with those who took tamoxifen. However, more strokes were seen among those receiving anastrozole. Data were not sufficiently mature to assess differences in death rates.

Women who took tamoxifen had more major thromboembolic events and gynecologic issues, including hot flashes, vaginal hemorrhage, and discharge, compared with those who took anastrozole. On the other hand, women who took anastrozole had more fractures, musculoskeletal issues, and vaginal dryness.

“We are continuing to follow the patients in this trial,” said Dr. Cuzick. “Analysis of molecular characteristics of the baseline cancers and those that develop on treatment is underway.”

This study was supported by Cancer Research UK, National Health and Medical Research Council Australia, the Breast Cancer Research Fund, and AstraZeneca. Dr. Cuzick received research grants from and is an ad hoc speaker for AstraZeneca. 

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement